September 30, 2016

CHDP Provider Information Notice No.: 16-08

TO: ALL CHILD HEALTH AND DISABILITY PREVENTION (CHDP) PROGRAM PROVIDERS AND MEDI-CAL MANAGED CARE PLANS

SUBJECT: AMENDMENT TO CHILD HEALTH DISABILITY AND PREVENTION (CHDP) PROGRAM PIN NO. 12-05 AND 10-09 AS WELL AS UPDATE PAYMENT FOR CODE 69 FOR MENINGOCOCCAL CONJUGATE VACCINE, MENVEO, NOVARTIS® (MENACWY-CRM 9)

The purpose of this Provider Information Notice (PIN) is to inform you about an amendment to CHDP Program Provider Information Notices No. 12-05 and No. 10-09, regarding the age range for Menveo®, A payment update has been made for CHDP Program Procedural Code 69. Effective February 1, 2016, Code 69, for Menveo only, will lower the starting age for administration of Menveo from nine (9) months to two (2) months of age. Thus, the code 69 update for Menveo® is for the Vaccines for Children (VFC) administration fee, two (2) months through 18 years, 11 months (except Menactra starts at 9 months through 18 years, 11 months).

Excerpt from the CHDP Provider Manual: Rates: Maximum Reimbursement for CHDP:

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Code</th>
<th>Vaccine Source</th>
<th>Age</th>
<th>Rate</th>
<th>Comment Required</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meningococcal Conjugate Vaccine (Menactra and Menveo)</td>
<td>69 11</td>
<td>VFC or State</td>
<td><strong>Menactra:</strong> 9 months thru 18 years, 11 months</td>
<td>$9.00</td>
<td>High risk factor if younger than 11 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Menveo®:</strong> 2 months thru 18 years, 11 months</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Background**

In accordance with the Advisory Committee on Immunization Practices (ACIP), October 2013 Recommendations and Practices meeting, recommend an additional
intramuscular vaccination option for infants age two (2) through 23 months at increased risk for meningococcal disease. MenACWY-CRM (Menveo®, Novartis) (MCV4) is an option for vaccinating infants age two (2) through 23 months that are at an increased risk for meningococcal disease. MenACWY-CRM (Menveo®, Novartis) is the first quadrivalent meningococcal conjugate vaccine licensed for use in children aged two (2) through eight (8) months.

As of October 2013, ACIP updated recommendations for MenACWY-CRM (Menveo®, Novartis) as an additional intramuscular meningococcal vaccine option for infants age two (2) through 23 months that are at an increased risk for meningococcal disease. The complete ACIP recommendations and resolutions for MenACWY-CRM (Menveo®, Novartis) can be found at the following Centers for Disease Control and Prevention (CDC) websites: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6324a2.htm and http://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/2015-06-15-mening.pdf.

The CHDP Program has determined to align policy for Code 69, MenACWY-CRM (Menveo®, Novartis) with an age and formulation-appropriate meningococcal conjugate vaccine recommended for infants aged two (2) through 23 months that are at an increased risk for meningococcal disease as described and referenced in the above CDC and ACIP websites. Infants that are at an increased risk for meningococcal disease are:

• those with persistent complement component deficiencies (C3, C5 - C9, properdin, factor D, and factor H) or taking eculizumab (Soliris®)

• those with functional or anatomic asplenia (including sickle cell disease)

• healthy infants in communities with a meningococcal disease outbreak for which vaccination is recommended

• those traveling to or residing in areas where meningococcal disease is hyperendemic or epidemic, particularly if contact with the local population will be prolonged (MenACWY vaccines only)

• children identified to be at increased risk because of a meningococcal disease attributable to serogroups A, C, W, or Y

Please note: Providers should not administer Menveo and Menactra together for children ages two (2) months through 23 months.
Reminder: Due to periodic outbreaks of meningitis making appropriate use of this vaccine is a high priority. Your continuing participation in the CHDP Program is greatly appreciated. If you have any questions, please contact your local CHDP program.

Sincerely,

ORIGINAL SIGNED BY ROBERT J. DIMAND

Robert J. Dimand, M.D.
Chief Medical Officer
Systems of Care Division